Literature DB >> 2305017

Metergoline abolishes the prolactin response to buspirone.

C A Gregory1, I M Anderson, P J Cowen.   

Abstract

Pretreatment of nine healthy subjects with the non-selective 5-HT receptor antagonist, metergoline (4 mg), abolished the increase in plasma prolactin produced by the anxiolytic drug, buspirone (15 mg). While these findings are consistent with a role for 5-HT receptors in the stimulatory effect of buspirone on plasma prolactin, a dopaminergic mechanism cannot be excluded by the present data.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305017     DOI: 10.1007/bf02244420

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Effects of methergoline on central monoamine neurones. Evidence for a selective blockade of central 5-HT receptors.

Authors:  K Fuxe; L Agnati; B Everitt
Journal:  Neurosci Lett       Date:  1975-11       Impact factor: 3.046

2.  Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.

Authors:  C Benkelfat; D L Murphy; J Zohar; J L Hill; G Grover; T R Insel
Journal:  Arch Gen Psychiatry       Date:  1989-01

3.  Dopamine receptor antagonism by the novel antianxiety drug, buspirone.

Authors:  B A McMillen; R T Matthews; M K Sanghera; P D Shepard; D C German
Journal:  J Neurosci       Date:  1983-04       Impact factor: 6.167

4.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  On the mode of the prolactin release-inhibiting action of the serotonin receptor blockers metergoline, methysergide, and cyproheptadine.

Authors:  L Krulich; S M McCann; M A Mayfield
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

6.  Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover.

Authors:  H Y Meltzer; M Simonovic; V S Fang; G A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion.

Authors:  C Ferrari; R Caldara; M Romussi; P Rampini; P Telloli; S Zaatar; G Curtarelli
Journal:  Neuroendocrinology       Date:  1978       Impact factor: 4.914

8.  The effect of buspirone on prolactin and growth hormone secretion in man.

Authors:  H Y Meltzer; R Flemming; A Robertson
Journal:  Arch Gen Psychiatry       Date:  1983-10

Review 9.  Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.

Authors:  E E Müller; V Locatelli; S Cella; A Peñalva; A Novelli; D Cocchi
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

Review 10.  Buspirone: review of its pharmacology and current perspectives on its mechanism of action.

Authors:  A S Eison; D L Temple
Journal:  Am J Med       Date:  1986-03-31       Impact factor: 4.965

View more
  4 in total

1.  Does metergoline selectively attenuate 5-HT mediated prolactin release?

Authors:  P M Ellis; S E Gartside; C J Ware; G M Campling; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers.

Authors:  I M Anderson; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome.

Authors:  A M Bakheit; P O Behan; T G Dinan; C E Gray; V O'Keane
Journal:  BMJ       Date:  1992-04-18

Review 4.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.